Ray Capital Management

Ray Capital Management is a Chinese investment management and private equity/venture capital firm rather than an operating biotech, pharma, or healthcare company. Publicly available information indicates it was established in 2019 in Hefei, Anhui, and is registered as a private fund manager focused on investment management, equity investment, and venture investment. The firm appears to have had some exposure to healthcare through association with Hasten Biopharmaceutic in China, which Takeda described as a company established by Ray Capital, but Ray Capital itself is not primarily a drug developer. There is no evidence that Ray Capital directly develops therapeutic products, runs a clinical pipeline, or operates as a life sciences platform company. For biotech analyst purposes, it should be classified as a financial sponsor/investment manager with selective healthcare-related involvement rather than as a healthcare operating company.